Current and future therapeutic approach for Waldenström's macroglobulinemia.

about

Current and future therapeutic approach for Waldenström's macroglobulinemia.

Item

http://www.wikidata.org/entity/Q38206820

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Current and future therapeutic approach for Waldenström's macroglobulinemia.

@en

type

Item

label

Current and future therapeutic approach for Waldenström's macroglobulinemia.

@en

prefLabel

Current and future therapeutic approach for Waldenström's macroglobulinemia.

@en

P1476

Current and future therapeutic approach for Waldenström's macroglobulinemia.

@en

P2093

Laetitia Souchet-Cömpain

http://www.w3.org/2001/XMLSchema#string

Stéphanie Nguyen

http://www.w3.org/2001/XMLSchema#string

Sylvain Choquet

http://www.w3.org/2001/XMLSchema#string

Véronique Leblond

http://www.w3.org/2001/XMLSchema#string

P2860

Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom's macroglobulinemia

MYD88 L265P somatic mutation in Waldenström's macroglobulinemia.

Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia

Gene-expression profiling of Waldenstrom macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myeloma

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

Thalidomide and rituximab in Waldenstrom macroglobulinemia

Long-term survival in Waldenstrom macroglobulinemia: 10-year follow-up of Southwest Oncology Group-directed intergroup trial S9003.

Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group.

Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia: results of WMCTG Trial 03-248.

Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia

P304

333-348

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/IMT.13.174

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2014-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24762077

http://www.w3.org/2001/XMLSchema#string